



Case report

Unreported cardiac arrhythmias in aluminium worker

Mustafa Yildiz, MD, Gonenc Kocabay, MD*



Kartal Kosuyolu Yuksek Ihtisas Heart Education and Research Hospital, Department of Cardiology, Kartal, Istanbul, Turkey

ARTICLE INFO

Article history:

Received 23 January 2013

Received in revised form

22 March 2013

Accepted 4 May 2013

Available online 12 June 2013

Keywords:

Cardiac arrhythmia

Atrioventricular block

Nonsustained ventricular tachycardia

Aluminium worker

ABSTRACT

Aluminium (Al) is the third most prevalent element, representing approximately 8% of total mineral components in the earth's crust (1). Chronic exposure to Al is mainly encountered at particular work places, for example, in foundries or in the Al powder industry, as an occupational exposure. In case of occupational Al exposure, inhalation is the main route of uptake. Chronic exposure to Al is associated with skeletal, neurological, hematological and lung changes. Studies regarding the Al powder industry showed that long-term inhalative exposure to Al can induce pulmonary fibrosis (2). Although there is only one report about ventricular tachycardia as a cardiac manifestation in occupationally exposed persons (3), in this report, we presented a case that had Mobitz type I second-degree atrioventricular block and nonsustained ventricular tachycardia. To our knowledge, this is the first report in chronic poisoning.

© 2013 Elsevier Ltd and Faculty of Forensic and Legal Medicine. All rights reserved.

1. Introduction

Aluminium (Al) is the third most prevalent element, representing approximately 8% of total mineral components in the earth's crust.¹ Chronic exposure to Al is mainly encountered at particular work places, for example, in foundries or in the Al powder industry, as an occupational exposure. In case of occupational Al exposure, inhalation is the main route of uptake. Chronic exposure to Al is associated with skeletal, neurological, hematological and lung changes. Studies regarding the Al powder industry showed that long-term inhalative exposure to Al can induce pulmonary fibrosis.² Although there is only one report about ventricular tachycardia as a cardiac manifestation in occupationally exposed persons,³ in this report, we presented a case that had Mobitz type I second-degree atrioventricular block and nonsustained ventricular tachycardia. To our knowledge, this is the first report in chronic poisoning.

2. Case report

A 42-year-old male patient – who formerly did not have any known disease – was admitted to emergency department of our hospital due to dizziness. His medical history showed that he had been exposed to aluminium steam in foundry work for 10 years. On his physical examination, blood pressure was 110/70 mmHg and pulse rate was arrhythmic with 60 beats/min. Electrocardiography

showed that he had Mobitz type I second-degree atrioventricular block (Fig. 1) and nonsustained ventricular tachycardia (Fig. 2). Blood tests were found normal except microcytic anemia. Serial creatinine kinase and troponin I were within normal limits. We did not find any electrolyte imbalance. A transthoracic echocardiogram was normal with left ventricular ejection fraction 60% and no significant valvar regurgitation. We performed coronary angiography to exclude ischemia and the results were normal. Supraventricular and ventricular tachycardia were not induced during electrophysiological investigation. Since he had no symptom and he was normotensive, we observed the patient without pacing.

Blood aluminium level was found 23.6 ug/L (reference range 0–14 ug/L) by atomic absorption method. We excluded lead intoxication which is also encountered in case of occupational Al exposure.

We considered this patient as an occupationally exposed person by reason of breathing aluminium steam for 10 years and having anemia.

Electrocardiographic findings were improved in the seventh day of hospitalization by the administration of 600 mg/day N-acetylcysteine (NAC) and hydration. 24-h Holter electrocardiogram recording revealed that he had sinus rhythm (average heart rate 74) with only four Mobitz type I second-degree atrioventricular block. He is asymptomatic and we advised him to change his work.

3. Discussion

Aluminum is increasingly used for the manufacture of many kinds of vehicles and in the construction industry due to its light weight, high durability and high electrical and thermal

* Corresponding author. Hurriyet Mahallesi, Uzmanlar Caddesi, Reyhan Sokak Burcu Temel Sitesi, E Blok, Kat 5, Daire 12, Yakacik, Kartal, Istanbul, Turkey. Tel.: +90 216 459 44 40; fax: +90 216 459 63 21.

E-mail address: gonenckocabay@yahoo.com (G. Kocabay).




Fig. 1. Electrocardiography revealed Mobitz type I second-degree atrioventricular block.

conductivity. In case of occupational Al exposure, inhalation is the main route of uptake. Therefore, toxicity is dependent on the species and particle size of the inhaled material.¹

Aluminium phosphide poisoning has a high mortality risk due to cardiovascular involvement. There are some reports about serious toxic effects of acute Al poisoning. Siwach and et al.⁴ reported 30 patients of acute Al poisoning. They observed life threatening ventricular tachycardia in 12 patients and ventricular fibrillation in 7 patients. One-third of the patients developed variable degrees of heart block. They accused toxic myocarditis that resulted from phosphine of these arrhythmias. In presented case, who have exposed Al for 10 years, we found serial cardiac markers such as troponin, creatine kinase-MB and echocardiographic investigation normal.




Fig. 2. Electrocardiography showed nonsustained ventricular tachycardia.

Soltaninejad and et al.⁵ evaluated the frequency of cardiac manifestations and electrocardiographic findings during acute AlP poisoning. They observed dysrhythmia in nine cases. Of them, seven patients showed atrial fibrillation and two cases had junctional rhythm. Additionally, they found that there was a significant correlation between cardiac dysrhythmia and mortality.

In our patient, we found microcytic anemia in blood tests. The current concept about the pathogenesis of aluminum-related microcytosis is that Al might interfere with iron kinetics at different levels, including alterations in delta amino levulinic dehydrase activity and intermediate porphyrin products and impaired intestinal iron absorption and cellular uptake.^{6,7} In conclusion, Al inhibits erythropoiesis and iron metabolism, probably hinders hemoglobin synthesis and erythroid cell maturation. Besides chelation therapy with deferoxamine, erythropoietin may prevent the oxidative stress due to Al exposure.⁸ Chronic Al exposure may lead to biochemical and morphological alterations similar to premature erythrocyte death (eryptosis), induced by oxidant compounds in human erythrocytes. Irrespective of the antioxidant mechanism, erythropoietin treatment benefits patients with anemia associated to altered redox environment.

An experimental study which was conducted by Lall and et al.⁹ showed that the effect of Al on heart is mediated by both declined cellular metabolism of the myocardium and by necrosis of the cardiac tissue resulting in the release of reactive oxygen intermediates. Tehrani and et al.¹⁰ showed the benefit of NAC in patients with acute aluminum phosphide poisoning. Additionally, NAC was found to be beneficial in rats. Treatment with NAC improved the survival due to the reduction of myocardial oxidative injury in this experimental study.^{11,12} The administration of a loading dose of NAC could treat the arrhythmia. Although these findings are valid in acute poisoning, we administered 600 mg/day NAC with hydration. On the seventh day of therapy, we performed 24-h Holter electrocardiogram recording. It revealed that he had sinus rhythm (average heart rate 74) with only four Mobitz type I second-degree atrioventricular block.

Other agents include trimetazidine, which switches myocyte metabolism to glucose from fatty acids, thus reducing oxygen consumption, and may have a potential role.¹³

In conclusion, Mobitz type I second-degree atrioventricular block might develop in occupationally exposed persons as well as nonsustained ventricular tachycardia. Additionally, since the correlation between cardiac dysrhythmia and mortality observed in previous studies, a clinical trial on the effectiveness of prophylactic administration of NAC in acute aluminum intoxication should be considered.

Ethical approval

None.

Funding

None.

Author contributions

All authors contributed to research design, or the acquisition, analysis or interpretation of data, to draft the paper and approved the final version.

Conflict of interest

None declared.

References

1. Rossbach B, Buchta M, Csanády GA, Filser JG, Hilla W, Windorfer K, et al. Biological monitoring of welders exposed to aluminium. *Toxicol Lett* 2006;**162**: 239–45.

2. Yokel RA, McNamara PJ. Aluminium toxicokinetics: an updated minireview. *Pharmacol Toxicol* 2001;**88**:159–67.
3. Yildiz M, Kocabay G, Ozkan M. Aluminium-induced ventricular tachycardia. *Am J Emerg Med* 2012;**30**:262.e1–2.
4. Siwach SB, Singh H, Jagdish, Katyal VK, Bhardwaj G. Cardiac arrhythmias in aluminium phosphide poisoning studied by on continuous holter and cardioscopic monitoring. *J Assoc Physicians India* 1998;**46**: 598–601.
5. Soltaninejad K, Beyranvand MR, Momenzadeh SA, Shadnia S. Electrocardiographic findings and cardiac manifestations in acute aluminum phosphide poisoning. *J Forensic Leg Med* 2012;**19**:291–3.
6. Cannata JB, Diaz López JB. Insights into the complex aluminium and iron relationship. *Nephrol Dial Transplant* 1991;**6**:605–7.
7. Caramelo CA, Cannata JB, Rodeles MR, Fernández Martín JL, Mosquera JR, Monzú B, et al. Mechanisms of aluminum-induced microcytosis: lessons from accidental aluminum intoxication. *Kidney Int* 1995;**47**:164–8.
8. Vota DM, Crisp RL, Nesse AB, Vittori DC. Oxidative stress due to aluminum exposure induces eryptosis which is prevented by erythropoietin. *J Cell Biochem* 2012;**113**:1581–9.
9. Lall SB, Sinha K, Mittra S, Seth SD. An experimental study on cardiotoxicity of aluminium phosphide. *Indian J Exp Biol* 1997;**35**:1060–4.
10. Tehrani H, Halvaie Z, Shadnia S, Soltaninejad K, Abdollahi M. Protective effects of N-acetylcysteine on aluminum phosphide-induced oxidative stress in acute human poisoning. *Clin Toxicol (Phila)* 2013;**51**:23–8.
11. Azad A, Lall SB, Mittra S. Effect of N-acetylcysteine and L-NAME on aluminium phosphide induced cardiovascular toxicity in rats. *Acta Pharmacol Sin* 2001;**22**: 298–304.
12. Bogle RG, Theron P, Brooks P, Dargan PI, Redhead J. Aluminium phosphide poisoning. *Emerg Med J* 2006;**23**:e3.
13. Dueñas A, Pérez-Castrillon JL, Cobos MA, Herreros V. Treatment of the cardiovascular manifestations of phosphine poisoning with trimetazidine, a new antiischemic drug. *Am J Emerg Med* 1999;**17**:219–20.